Drug Type Monoclonal antibody |
Synonyms HL 05, HL-05, HL05 |
Target |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bone metastases | Phase 3 | CN | 16 Feb 2023 | |
Solid tumor | Phase 3 | CN | 16 Feb 2023 |